Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
VRTX: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: Financial results
Filed 8-K for an event or period dated 2026-11-02. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
Access to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
Public: Oct 20, 2026, 10:46 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to tariff and trade policy.
Public: Oct 20, 2026, 5:54 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
International trade issues impacting pharmaceutical industry.
Public: Oct 20, 2026, 4:36 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; Kidney care issues; FY27 LHHS and Mil-Con appropriations report language Monitor issues related to 340b;
Public: Oct 20, 2026, 4:18 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: Leadership change
Filed 8-K for an event or period dated 2026-10-20. Leadership change.
1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
Federal budget issues Lobbying related to pharmaceutical policy Lobbying related to pharmaceutical and Medicare/Medicaid policy
Public: Oct 20, 2026, 3:51 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
FY2027 Appropriations bills. FY2027 Appropriations bills.
Public: Oct 20, 2026, 3:26 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
Public: Oct 20, 2026, 12:13 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
Issues related to Kidney health, HR 1227 Alternatives to Pain Act.
Public: Oct 19, 2026, 5:33 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS. Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37). Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process. Issues related
Public: Oct 19, 2026, 3:22 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/
Public: Oct 17, 2026, 6:25 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: first_quarter 2025 lobbying report
Supporting Vertex on trade-related issues.
Public: Oct 7, 2026, 5:00 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2026 lobbying report
Tax Reform - Restoring the Orphan Drug Tax Credit.
Public: Oct 7, 2026, 1:42 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: Leadership change
Filed 8-K for an event or period dated 2026-08-27. Leadership change.
1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: Financial results
Filed 8-K for an event or period dated 2026-08-03. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: fourth_quarter 2024 lobbying report
federal budget issues IRA implementation, innovation, health disparities, orphan drugs, 340B, opioid alternative medicine, SUPPORT Act reauthorization Medicare & Medicaid payment and coverage issues orphan drug tax credit
Public: Aug 3, 2026, 10:14 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: third_quarter 2024 lobbying report
federal budget issues IRA implementation, innovation, health disparities, orphan drugs, 340B, opioid alternative medicine, SUPPORT Act reauthorization Medicare & Medicaid payment and coverage issues orphan drug tax credit
Public: Aug 3, 2026, 10:13 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: second_quarter 2024 lobbying report
federal budget issues IRA implementation, innovation, health disparities, orphan drugs, 340B, opioid alternative medicine, SUPPORT Act reauthorization Medicare & Medicaid payment and coverage issues orphan drug tax credit
Public: Aug 3, 2026, 10:12 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: first_quarter 2024 lobbying report
federal budget issues IRA implementation, innovation, health disparities, orphan drugs, 340B, opioid alternative medicine, SUPPORT Act reauthorization Medicare & Medicaid payment and coverage issues orphan drug tax credit
Public: Aug 3, 2026, 10:11 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: second_quarter 2026 lobbying report
FY2027 Appropriations bills. FY2027 Appropriations bills.
Public: Jul 20, 2026, 7:38 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: second_quarter 2026 lobbying report
A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.
Public: Jul 20, 2026, 7:21 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
VRTX: second_quarter 2026 lobbying report
Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
Public: Jul 20, 2026, 2:49 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:36 PM EST
- USAspending
- Collection in progress68 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:27 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:39 PM EST
- Federal Register
- Collection in progress295 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:39 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable33 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:39 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST